Am Fam Physician. 2012 Apr 15;85(8):online.
Original Article: Update on Vitamin B12 Deficiency
Issue Date: June 15, 2011
Available at: http://www.aafp.org/afp/2011/0615/p1425.html
to the editor: As a special consideration, the authors of this article mention the current lack of evidence supporting vitamin B12 supplementation for the treatment of Alzheimer disease and other types of dementia. We have also been discouraged by the paucity of studies demonstrating the effectiveness of vitamin supplementation in the treatment of cognitive decline, and thought it pertinent to also raise the point of cost consideration.
The American Academy of Neurology guidelines on cognitive impairment state that screening instruments, such as the Mini-Mental State Examination, may be helpful diagnostic tools.1 The physician is advised to rule out structural defects, depression, hypothyroidism, and vitamin B12 deficiency as causes of the cognitive impairment. The U.S. Department of Health and Human Services publishes an annual overview of Medicare reimbursement rates for such laboratory tests. It states that measurement of vitamin B12 costs $21.59, measurement of folate costs $21.06, and measurement of homocysteine costs $24.16.2
Although the cost of measuring vitamin B12 is small, given the frequency with which it is performed, there is considerable cost to society. The Geriatric Mental Health Foundation estimates that 360,000 new diagnoses of Alzheimer disease are made each year, and the number of diagnostic examinations performed is expected to triple in the next 50 years as the Baby Boomer generation ages.3 Cost-effective, evidence-based guidelines are needed to direct the evaluation of dementia in an aging population, because there is a strong trend toward the use of broad diagnostic panels instead of specific tests based on clinical judgment.
Routine measurement of vitamin B12 may not be necessary in the absence of symptoms suggesting pernicious anemia or in the presence of severe malnutrition. Assuming that most diagnostic workups for dementia are paid from Medicare reimbursements, the cost of vitamin investigation would incur a charge of more than $7 million annually for Alzheimer disease diagnoses. This figure does not include patients tested who ultimately are not diagnosed with Alzheimer disease, and would be expected to increase with the aging population. If examined from the standpoint of cost-benefit ratio to the individual and to society, it would seem that having a fixed “dementia panel” covering many remote possibilities offers very little beyond what can be suspected and detected by an observant physician who obtains an adequate history and performs an adequate physical and mental status examination.
1. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133–1142.
2. U.S Department of Health and Human Services. Clinical laboratory fee schedule 2010. http://www.cms.gov/ClinicalLabFeeSched/. Accessed December 5, 2011.
3. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of alzheimer's disease incidence rates. Alzheimers Dement. 2008;4(5):316–323.
in reply: I sincerely appreciate the comments and observations from Drs. Warren and Weiner concerning the not insignificant financial ramifications of the widespread use of “shotgun” testing, including vitamin B12 testing for dementia. In an era of evidence-based clinical practice guidelines, it is tempting to excuse the nonjudicious use of laboratory and imaging studies as simply following recommendations from reputable sources. As physicians, it is imperative that we listen, examine, and form opinions. Only then should we seek to confirm potential diagnoses with laboratory or imaging studies, rather than substituting a standard array of tests for our interpersonal relationships and clinical skills. We would do well to heed the advice attributed to Sir William Osler: “Listen to the patient. He is telling you the diagnosis.”
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2012 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions